Literature DB >> 10676637

Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu.

H Roh1, J Pippin, J A Drebin.   

Abstract

The HER2/neu oncogene is overexpressed in a significant fraction of human tumors; such overexpression is thought to play a role in the aberrant proliferation of cancer cells. The effects of HER2/neu-specific phosphorothioate antisense oligodeoxyribonucleotides on HER2/neu expression, tumor cell proliferation, and activation of apoptotic cell death pathways have been examined. Antisense treatment down-regulates HER2/neu expression in a dose-dependent and sequence-specific manner. HER2/neu antisense treatment specifically inhibits the growth of tumor lines that overexpress HER2/neu, but it has little effect on the growth of tumor cells that express low levels of HER2/neu. Down-regulation of HER2/neu expression is not only cytostatic, but it also results in the activation of apoptotic cell death pathways in cells that overexpress HER2/neu. These results suggest that, in addition to stimulating tumor cell proliferation, HER2/neu overexpression in cancer cells acts as an antiapoptotic cell survival factor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10676637

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor.

Authors:  D C Márquez; J Lee; T Lin; R J Pietras
Journal:  Endocrine       Date:  2001-11       Impact factor: 3.633

Review 2.  Perspectives of HER2-targeting in gastric and esophageal cancer.

Authors:  James N Gerson; Sam Skariah; Crystal S Denlinger; Igor Astsaturov
Journal:  Expert Opin Investig Drugs       Date:  2017-05       Impact factor: 6.206

3.  Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells.

Authors:  Timo Faltus; Juping Yuan; Brigitte Zimmer; Andrea Krämer; Sibylle Loibl; Manfred Kaufmann; Klaus Strebhardt
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

Review 4.  The role of HER2 in cancer therapy and targeted drug delivery.

Authors:  Wanyi Tai; Rubi Mahato; Kun Cheng
Journal:  J Control Release       Date:  2010-04-10       Impact factor: 9.776

5.  Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts.

Authors:  Judy Wang; Paul Chen; Marko Mrkobrada; Meiduo Hu; Katherine A Vallis; Raymond M Reilly
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-15       Impact factor: 9.236

Review 6.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

7.  External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator.

Authors:  Shinichi Asada; Yongmun Choi; Masaki Yamada; Shao-Chun Wang; Mien-Chie Hung; Jun Qin; Motonari Uesugi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

8.  A novel interaction between HER2/neu and cyclin E in breast cancer.

Authors:  E A Mittendorf; Y Liu; S L Tucker; T McKenzie; N Qiao; S Akli; A Biernacka; Y Liu; L Meijer; K Keyomarsi; K K Hunt
Journal:  Oncogene       Date:  2010-05-10       Impact factor: 9.867

Review 9.  Targeting the function of the HER2 oncogene in human cancer therapeutics.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

10.  Enhanced Human Epidermal Growth Factor Receptor 2 Degradation in Breast Cancer Cells by Lysosome-Targeting Gold Nanoconstructs.

Authors:  Hyojin Lee; Duncan Hieu M Dam; Ji Won Ha; Jun Yue; Teri W Odom
Journal:  ACS Nano       Date:  2015-09-03       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.